Case 105 update 2

Our patient was discussed at MDT and as many have suggested, he is treated with intensive chemotherapy.

MATRIX – HD MTX, cytarabine, thiotepa and rituximab is the current regime recommended in the UK.  Intrathecal chemotherapy is not advocated in the BSH guidelines.  MTX should be delivered at doses of at least 3g/m2 with an infusion time of 2-4 hours.

He had a repeat MRI after two cycles showing complete remission.  His stem cells were harvested after the second cycle. He goes onto to have a further 2 cycles of MATRIX followed by autologous stem cell transplant.

Repeat MRI at 6 weeks following treatment shows no evidence of disease.  However 5 months following ASCT he presents with slurred speech and further MRI shows two new cerebral lesions.

 

What is your differential? Management plan?

 

 

About TeamHaem

Online education and discussion about all things haematological
This entry was posted in Uncategorised. Bookmark the permalink.